Target trial emulation reveals semaglutide reduces epilepsy risk in adults with type 2 diabetes, suggesting potential benefits.
To determine whether semaglutide reduces the risk of incident adult-onset epilepsy or seizures in adults with type 2 diabetes compared with sodium–glucose cotransporter-2 inhibitors (SGLT2i) and other glucose-lowering drugs (GLDs).
No takes yet. Share an insight, caveat, or question.
Eun et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: